AmMax Bio., Inc.

Pharmaceutical ManufacturingCalifornia, United States11-50 Employees

AmMax Bio., Inc. is a private, clinical-stage biopharmaceutical company focused on oncology, developing therapeutics grounded in translational science and drug development. It is based in Redwood City, California, and was founded in 2020 as part of a partnership with Amgen, which granted AmMax an exclusive worldwide license to a CSF1R-targeting monoclonal antibody and included Amgen taking a minority stake. The core pipeline comprises AMB-066, a CSF1R-targeting monoclonal antibody in Phase 2a for colorectal cancer minimal residual disease, and AMB-104, an antibody-drug conjugate intended for AML and potentially solid tumors, built on a linker-payload platform.

The management team includes Dr. Larry Hsu, a co-founder and former CEO of Impax Laboratories, who brings broad experience across therapeutic areas and modalities and has led teams through product approvals. In 2026, Lonza Group announced an integration with AmMax Bio to advance AMB-104, combining AmMax’s antibody with Lonza’s technology to pursue a tumor-targeted cytotoxic payload for hematologic cancers. The company positions itself as a clinical-stage biotechnology player focused on oncology, supported by collaborations and a pipeline spanning solid tumors and hematologic cancers.

Sign up for free to view info

Email Format Employee directory